The burgeoning popularity of tirzepatide , initially for blood sugar control , is creating significant attention within the UK , prompting a notable shift in peptide trends. Access these treatments remains a complex situation , with NHS approval currently limited and specialist practices offering therapy at a higher cost . Concerns are being raised